Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Microbiological Comparison of Initial and Subsequent Healthcare-Associated Infections in the Intensive Care Unit

NCT07916649 is registered in ClinicalTrials.gov with Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07916649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Microbiological Comparison of Initial and Subsequent Healthcare-Associated Infections in the Intensive Care Unit
Lead sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
October 1, 2026
Completion date
October 30, 2026
Enrollment
243 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cross infection, intensive care units, microbial disease

Arms

As registered; 2 arms.

  • Patients With Subsequent Healthcare-Associated Infections

    Adult patients who developed at least one healthcare-associated infection (HAI) during their intensive care unit (ICU) stay and subsequently experienced a new HAI during the same hospitalization. The first HAI will be defined as the index infection, and the first subsequent new HAI will be evaluated according to CDC/NHSN surveillance criteria, including the 14-day repeat infection timeframe. Clinical and microbiological characteristics of the index and subsequent infections will be compared using paired patient data. No study-specific interventions will be performed.

  • Patients Without Subsequent Healthcare-Associated Infections

    Adult patients who developed at least one healthcare-associated infection (HAI) during their intensive care unit (ICU) stay but did not experience a subsequent new HAI during the same hospitalization. The first HAI will be defined as the index infection. Demographic and clinical characteristics at the time of the index infection will be evaluated and compared with those of patients who developed subsequent HAIs. No study-specific interventions will be performed.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Change in Infection Site Between Index and First Subsequent Healthcare-Associated Infections At diagnosis of the index healthcare-associated infection (baseline) and at diagnosis of the first subsequent healthcare-associated infection during the same ICU stay, assessed up to 120 days after baseline.

    Among patients who develop a subsequent healthcare-associated infection (HAI), infection sites will be compared between the index infection and the first subsequent infection using paired patient-level data. Changes in infection sites will be assessed using the number and percentage of patients with different infection sites between episodes. Infection-site distributions and transitions will be presented using frequency tables and transition matrices.

  • Change in Causative Microorganisms Between Index and First Subsequent Healthcare-Associated Infections At diagnosis of the index healthcare-associated infection (baseline) and at diagnosis of the first subsequent healthcare-associated infection during the same ICU stay, assessed up to 120 days after baseline.

    Among patients who develop a subsequent healthcare-associated infection (HAI), causative microorganisms identified during the index infection and the first subsequent infection will be compared using paired patient-level data. Changes in causative microorganisms will be evaluated based on microbiological records. The number and percentage of patients with changes in causative microorganisms will be reported, and microorganism transitions will be summarized using frequency distributions and transition tables.

Papers

PubMed papers this trial cites; 3 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, most recent start first.

Similar trials

Same condition (Cross Infection) and phase, most recent start first.